A transducer apparatus for delivering tumor treating fields to a subject's body, the transducer apparatus including: an array of electrodes, the array configured to be positioned over the subject's body with a face of the array facing the subject's body, the array including electrode elements positioned in existing electrode positions arranged around a centroid of the array; and at least one void space in the array capable of enclosing an areal footprint equivalent to at least 40% of an areal footprint of at least one existing electrode position, and superimposable on at least 40% of at least one existing electrode position by rotation of the array around the centroid.

A transducer apparatus for delivering tumor treating fields to a subject's body, the transducer apparatus including: an array of electrodes configured to be positioned over the subject's body with a face of the array facing the subject's body; a substrate including an adhesive layer, wherein the array of electrodes is disposed entirely on a first side of the substrate, the face of the array faces away from the substrate, the adhesive layer is on the first side of the substrate facing the same direction as the face of the array; and, when viewed from a direction perpendicular to the face of the array, a non-adhesive region is located between a pair of adjacent electrodes of the array, the non-adhesive region spanning at least 25% of a total distance between the pair of adjacent electrodes for at least one measurement measured along a straight line between the pair of adjacent electrodes.

A transducer apparatus for delivering tumor treating fields to a subject's body, the transducer apparatus including: a substrate and an array of electrodes disposed on the substrate, the array configured to be positioned over the subject's body with a face of the array facing the subject's body; wherein, when viewed from a direction perpendicular to the face of the array, the substrate has at least one concave edge forming at least a portion of a boundary of the array, the at least one concave edge defines an opening between two opposing sides of the substrate, no electrodes are present in the opening, and the substrate has a substantially C-shaped, U-shaped, rounded V-shaped, or annular shaped surface.

A system for detecting presence of coronavirus in a subject, the system including a first pad for placing a first hand, the pad including a contact to measure conductance of the subject's body, a conductance meter connected to the contact, a second pad for placing a second hand, a source of electromagnetic radiation for irradiating the second pad.

A system for detecting presence of coronavirus in a subject, the system including a chip with a plurality of wires disposed on or in the chip, a conductance meter arranged to measure conductance between the wires, and biological material associated with the coronavirus disposed on or in the chip.

Related apparatus and methods are also described.

Apparatus and methods for imposing electric fields through a target region in a body of a patient are described. Generally, the apparatus may include an electric field generator having a first circuit generating a first output signal having a positive voltage; a second circuit generating a second output signal having a negative voltage, and a processor executing processor executable instructions to alternatingly enable the first output signal, and the second output signal to a first port and a second port to generate an alternating current square wave in a frequency range from 50 kHz to 1 MHz.

A system and method are herein described. The system comprises two or more transducer arrays, each of the two or more transducer arrays comprising one or more first connector; a garment comprising a supporting layer and one or more second connector; a pump configured to selectively provide a fluid at one or more predetermined pressure; an inflatable component comprising one or more bladder and supported by the supporting layer at a location associated with the treatment area, the one or more bladder biased to a neutral position and configured to expand to an inflated position based in part on the one or more predetermined pressure, the one or more bladder in the inflated position providing a biasing pressure against a particular transducer array to cause the particular transducer array to conform to a subject's body; and a tube configured to provide fluid communication between the pump and the inflatable component.

An assembly for delivering tumor-treating fields to a body of a patient can include an electrode subassembly and one or more replaceable adhesive subassemblies. Each adhesive subassembly can have a support layer having a first side and a second side. The support layer can define at least one opening. Each electrode of the electrode subassembly can be received within a respective opening of the at least one opening. A first adhesive can be disposed on the first side of the support layer and can couple the support layer to an inner side of a covering layer of the electrode subassembly at an attachment surface of the covering layer. A biocompatible conductive adhesive can be disposed on the second side of the support layer.

A method of determining susceptibility of cancer cells to treatment with alternating electric fields, or of reducing the viability of cancer cells by applying alternating electric fields, by measuring percentage of ciliated cancer cells or by measuring average length of a primary cilia of cancer cells. A method of treating Huntington's disease by applying alternating electric fields to a brain of a subject.

Methods for treating a human patient diagnosed with cancer with therapeutic neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological processes associated with the progression of cancer. One aspect of the present technology is directed to methods that attenuate neural traffic along target sympathetic nerves innervating tissue proximate a primary malignant tumor. Other aspects are directed to methods that at least partially inhibit sympathetic neural activity in a renal nerve of a patient diagnosed with cancer or who has a high risk of developing cancer. Targeted sympathetic nerve activity can be attenuated to improve a measurable physiological parameter corresponding to the progression of cancer in the patient. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g., a therapeutic assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the target sympathetic nerve.

An optimization of electrical characteristics for treatments of tumor or other abnormal cells in culture with sub-microsecond, high-electric field electrical pulses is disclosed. The voltages, pulse widths, and number of pulses are chosen such that the treatment energy is 10-20 J/mL. That is, U=n*Δt*V*I/volume is 10-20 J/mL, in which n is the number of pulses, Δt is the duration of each pulse, V is the voltage, I is current, and volume is the area of parallel electrodes times the distance between them. V divided by the distance between the electrodes can be in an effective range of 6 kV/cm to 30 kV/cm, 60 kV/cm, 100 kV/cm, or higher intensities. Rows of needle electrodes, blade electrodes, or other configurations of electrodes can approximate parallel electrodes.